^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    letaplimab (IBI188)

    i
    Other names: IBI188, IBI 188, IBI-188
    Associations

    News

    Trials
    Company:
    Innovent Biologics
    Drug class:
    CD47 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    Anti-CD47 drug interference in pre-transfusion testing can be overcome by antigen masking. (PubMed, Transfusion)
    These findings emphasize the need for awareness and adaptation in immunohematology practices as anti-CD47 drugs continue to advance in clinical development, and highlight the utility of antigen masking strategies to enhance the safe administration of blood products to treated patients.
    Journal
    |
    CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    magrolimab (ONO-7913) • lemzoparlimab (ABBV-IMAB-TJC4) • ligufalimab (AK117) • letaplimab (IBI188) • ontorpacept (PF-07901800)
    over2years
    Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=222, Suspended, Innovent Biologics (Suzhou) Co. Ltd. | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    azacitidine • decitabine • letaplimab (IBI188)
    over3years
    Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=222, Suspended, Innovent Biologics (Suzhou) Co. Ltd. | N=126 --> 222 | Trial completion date: May 2022 --> Jun 2024 | Recruiting --> Suspended | Trial primary completion date: Apr 2021 --> Jun 2023
    Enrollment change • Trial completion date • Trial suspension • Trial primary completion date • Combination therapy
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    azacitidine • decitabine • letaplimab (IBI188)
    over4years
    Suppression of Extracellular Vesicle CD47 Induces Systemic Anti-DLBCL Immunity (ASH 2021)
    Anti-CD47 antibody (IBI188) has shown promise in treating tumors, including Diffuse large B cell lymphoma (DLBCL)...Moreover, high levels of circulating EV CD47 would follow and correlate positively with the phagocytic activity of macrophages, and reflect the presence of a successful anti-tumor immunity elicited by the anti-CD47 therapy. Together, these findings show that EV CD47 represents an unexplored therapeutic target, which could overcome resistance to current CD47 antibody approaches.
    IO biomarker
    |
    CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    letaplimab (IBI188)